

which are present as racemates and also as D- or L- configured compounds and in which


R¹

- (a) is OH or OR⁴, where R⁴ is unsubstituted or substituted, branched or unbranched C₁-C₈-alkyl, C₃-C₈-cycloalkyl or aralkyl,

- (b) represents a group of the formula
- $$\begin{array}{c} \text{R}^5 \\ \diagup \\ \text{N} \\ \diagdown \\ \text{R}^6 \end{array}$$

in which R⁵ and R⁶ are any radicals, where in particular

- (i) R⁵ and R⁶ are H,
- (ii) R⁵ is H and R⁶ is unsubstituted or substituted, branched or unbranched C₁-C₈-alkyl, aralkyl or C₅-C₈-cycloalkyl,
- (iii) R⁵ and R⁶ are in each case independently unsubstituted or substituted, branched or unbranched C₁-C₄-alkyl or
- (iv) R⁵ is H and R⁶ is -NH₂ or is, in particular, an aryl-substituted or heteroaryl-substituted amino group,
- (v) R⁵ is H or unsubstituted or substituted, branched or unbranched C₁-C₄-alkyl or R⁶ is an amino acid residue, a peptide residue or a polypeptide residue,
- (c) represents a group of the formula




RECEIVED
JUL 30 2002
TECHNICAL CENTER 1600/2900

B

in which m is the number 1 or 2 and in which one or more of the methylene groups are unsubstituted or substituted, with the group (c) being racemic or in D or L configuration, and R^7 has the meaning of R^1 in subsections (a), (b) and (f),


(d) represents a group of the formula



in which $p=r=1$, $p=1$ and $r=2$ or $p=2$ and $r=1$ and in which one or more of the methylene groups are unsubstituted or substituted and R^7 had the meaning of R^1 in subsections (a), (b) and (f),

(e) represents a piperidyl group which is unsubstituted or substituted in one of positions 2, 3 or 4, where a further aromatic or cycloaliphatic ring is optionally fused to the heterocycloaliphatic rings of the formulae (c), (d) and (e) in the 2,3 position or the 3,4 position relative to the heteroatom,

(f) represents a group of the formula



in which R^8 is

- (i) unsubstituted or substituted C_1 - C_6 -alkyl or aryl,
- (ii) saturated or unsaturated, unbranched or branched C_1 - C_6 -alkoxy or

- ~~(iii) unsubstituted or substituted phenoxy or benzyloxycarbonyl,~~
- (g) represents an acyl radical of the formula $-COX$, where X is
- ~~(i) H, unsubstituted or substituted, unbranched or branched alkyl~~
 - ~~(ii) unsubstituted or substituted aryl or heteroaryl, or~~
 - ~~(iii) unsubstituted or substituted cycloalkyl,~~
- (h) represents aralkyl in which the aromatic radical is unsubstituted or substituted,
- (i) represents a carboxamide radical of the formula $-CONR'R''$, a thiocarboxamide radical, $-CSNR'R''$ or an acetamide radical $-CH_2-CONR'R''$ where
- (i) R' and R'' are H,
 - (ii) R' and R'' are in each case independently C_1-C_4 -alkyl,
 - (iii) R' is H and R'' is C_1-C_4 -alkyl,
 - (iv) R' is H and R'' is aryl, or
 - (v) R' and R'' constitute together with the nitrogen atom a heterocycloaliphatic ring having 5-7 ring members and possibly having a further heteroatom,
- (j) represents SO_2-Y where Y is
- (i) unsubstituted or substituted C_1-C_8 -alkyl,
 - (ii) unsubstituted or substituted aryl or heteroaryl or O-aryl or O-heteroaryl or
 - (iii) $-NR'R''$, where R' and R'' are in each case independently H or C_1-C_3 -alkyl,

(k) represents a cycloaliphatic unsubstituted or substituted ring having from 5 to 8 carbon atoms,

(l) represents an unsubstituted or substituted heteroaryl or heterocycloaliphatic radical,

(m) represents a functionalized alkyl radical of the formula $-(CH_2)_n-X$, where the alkyl chain is unbranched or branched, $n = 1$ to 8, and the functional radical X

(i) represents a hydroxyl group whose hydrogen atom is unsubstituted or substituted by C_1-C_4 -alkyl-, aralkyl-, e.g. benzyl or phenylethyl, aryl, C_1-C_4 -hydroxyalkyl or acyl group CO-alkyl (C_1-C_6),

(ii) is a halogen atom

(iii) represents a tertiary amino group of the formula $-N(alk)_2$, where the alkyl groups have 1 to 3 carbon atoms and the nitrogen atom may belong to a heterocycloaliphatic ring having 5-7 ring members and possibly having a further heteroatom, S,

R^2 represents unsubstituted or substituted phenyl,

R^3 is H or branched or unbranched C_1-C_4 -alkyl, and n is 0 or 1,

Sub

B1 C9

or a salt of said compound.

Amend claim 2 and 3 as follows:

2. Amended The method of claim 19, wherein R^1 is a group of the formulae (b), (d) and (f), R^2 represents 2, 4, 6 triisopropylphenyl, and $n=0$.

3. Amended The method of claim 19, wherein the compound of the formula I is $N\alpha$ -(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(D,L)-phenyl-alanine 4-ethoxycarbonylpiperazide, is the L enantiomer or a pharmaceutically suitable salt of one of the compounds.

4. Amended The method of claim 19, characterized in that the compounds are present in the form of physiologically acceptable acid salts, in particular as hydrochlorides.

Cancel claim 5 and rewrite as the following new claim:

-- 20. The method of claim 19, wherein the method is a method of controlling tumors.

Cancel claim 6 and replace by the following new claim:

-- 21. The method of claim 19, wherein the method controls breast carcinomas, pancreatic carcinomas or the formation of metastases.

Cancel claim 7 and replace by the following new claim:

-- 22. The method of claim 19, wherein the method is for controlling pemphigus vulgaris.

Amend claims 8, 9 and 11 as follows:

6. Amended The method as claimed in claim 19, wherein the compounds of the formula I are used coupled with further pharmacologically active substances.